The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Aglaia Biomedical Ventures; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; MSD
Speakers' Bureau - Bristol-Myers Squibb; MSD
Research Funding - Astellas Pharma; Bayer; Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech
 
Ronald De Wit
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Sanofi (Inst)
 
David J. Vaughn
Consulting or Advisory Role - Astellas Pharma
 
Yves Fradet
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck; Roche
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Roche
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Exelixis; Janssen; Novartis; Pfizer
 
Lawrence Fong
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Oncosec (Inst); Roche/Genentech (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Miguel Ángel Climent
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Pfizer
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; progenics; Progenics; Sanofi
Expert Testimony - Celgene; sanofi
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy
 
Andrea Necchi
No Relationships to Disclose
 
Winald Gerritsen
No Relationships to Disclose
 
Howard Gurney
Honoraria - Astellas Pharma; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Sanofi
 
David I Quinn
Honoraria - EMD Serono
Consulting or Advisory Role - EMD Serono
 
Stephane Culine
Consulting or Advisory Role - Janssen; Roche
Research Funding - Astellas Pharma; MSD; Roche
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen
 
Cora N. Sternberg
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Ipsen; Janssen; Lilly; MSD; Novartis; Pfizer; Sanofi
Research Funding - Exelixis (Inst)
 
Yabing Mai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Markus Puhlmann
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
Other Relationship - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer